Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome

Endocrinology (United States)

Volumn 155, Issue 9, 2014, Pages 3684-3693

  Leblanc, Samuel ^a   Battista, Marie Claude ^a   Noll, Christophe ^a   Hallberg, Anders ^b   Gallo Payet, Nicole ^a,d   Carpentier, André C ^a,d   Vine, Donna F ^c   Baillargeon, Jean Patrice ^a,d  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF ALBERTA   (Canada)

^d Centre Hospitalier Universitaire de Sherbrooke   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR AGONIST; ANGIOTENSIN DERIVATIVE; FATTY ACID; HEPTADECANOIC ACID; HORMONE RECEPTOR AFFECTING AGENT; INSULIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG UPTAKE; FEMALE; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MEDICAL INFORMATION; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; RAT; TESTOSTERONE BLOOD LEVEL; ANIMAL; BLOOD; DRUG POTENTIATION; GENETICS; HUMAN; METABOLISM; OVARY; TRANSGENIC RAT; UPREGULATION;

ANIMALS; FATTY ACIDS; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN; INSULIN RESISTANCE; OBESITY; OVARY; POLYCYSTIC OVARY SYNDROME; RATS; RATS, TRANSGENIC; RECEPTOR, ANGIOTENSIN, TYPE 2; TESTOSTERONE; UP-REGULATION;

EID: 84907057385     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1185     Document Type: Article

References (61)

1. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome asapredominantly hyperan-drogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237-4245.
2. Baptiste CG, Battista M-C, Trottier A, Baillargeon J-P. Insulin and hyperandrogenismin women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122(1-3):42-52.
3. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165-1174.
4. Azziz R, Black V, Hines GA, Fox LM, Boots LR. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab. 1998;83(7):2317-2323.
5. Ibañez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with poly-cystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab. 1996; 81(11):4103-4107.
6. De Fronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pr Suppl. 2004;143:9-21.
7. Carpentier AC. Postprandial fatty acid metabolism in the development of lipotoxicity and type 2 diabetes. Diabetes Metab. 2008; 34(2):97-107.
8. Mai K, Bobbert T, Kullmann V, et al. Free fatty acids increase an-drogen precursors in vivo. J Clin Endocrinol Metab. 2006;91(4): 1501-1507.
9. Mai K, Bobbert T, Reinecke F, et al. Intravenous lipid and heparin infusion-induced elevation in free fatty acids and triglycerides modifies circulating androgen levelsin women: arandomized, controlled trial. J Clin Endocrinol Metab. 2008;93(10):3900-3906.
10. Bellanger S, Battista MC, Fink GD, Baillargeon JP. Saturated fatty acid exposure induces androgen overproduction in bovine adrenal cells. Steroids. 2012;77(4):347-353.
11. Gallo-Payet N, Shum M, Baillargeon JP, et al. AT2 receptor agonists: exploiting the beneficial arm of Ang II signaling Implication in adipocyte physiology and in insulin resistance. Curr Hypertens Rev. 2012;8(1):47-59.
12. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol. 2009;302(2):128-139.
13. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev. 2003;4(1):43-55.
14. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52(3):415-472.
15. Steckelings UM, Rompe F, Kaschina E, et al. The past, present and future of angiotensin II type 2 receptor stimulation. J Renin Angio-tensin Aldosterone Syst. 2010;11(1):67-73.
16. Tanaka M, Ohnishi J, Ozawa Y, et al. Characterization of angio-tensin II receptor type 2 during differentiation and apoptosis of rat ovarian cultured granulosa cells. Biochem Biophys Res Commun. 1995;207(2):593-598.
17. Peters B, Clausmeyer S, Teubner P, et al. Changes of AT(2) receptor levels in the rat adrenal cortex and medulla induced by bilateral nephrectomy and its modulation by circulating ANGII. J Histochem Cytochem. 2001;49(5):649-656.
18. Steckelings UM, Widdop RE, Paulis L, Unger T. The angiotensin AT2 receptor in left ventricular hypertrophy. J Hypertens. 2010; 28(suppl 1):S50-S55.
19. Siragy HM. The angiotensin II type 2 receptor and the kidney. J Renin Angiotensin Aldosterone Syst. 2010;11(1):33-36.
20. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension. 2007;49(2):341-346.
21. Lemarié CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2010; 11(1):19-31.
22. McCarthy CA, Widdop RE, Denton KM, Jones ES. Update on the angiotensin AT(2) receptor. Curr Hypertens Rep. 2013;15(1):25-30.
23. Verdonk K, Danser AH, van Esch JH. Angiotensin II type 2 receptor agonists: where should they be applied? Expert Opin Investig Drugs. 2012;21(4):501-513.
24. Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol. 2010;7(8):431-441.
25. Pucell AG, Hodges JC, Sen I, Bumpus FM, Husain A. Biochemical properties of the ovarian granulosa cell type 2-angiotensin II receptor. Endocrinology. 1991;128(4):1947-1959.
26. Portela VM, Gonçalves PB, Veiga AM, Nicola E, Buratini J Jr, Price CA. Regulation of angiotensin type 2 receptor in bovine granulosa cells. Endocrinology. 2008;149(10):5004-5011.
27. Schauser KH, Nielsen AH, Winther H, Dantzer V, Poulsen K. Localization of the renin-angiotensin system in the bovine ovary: cyclic variation of the angiotensin II receptor expression. Biol Reprod. 2001;65(6):1672-1680.
28. Yoshimura Y, Karube M, Aoki H, et al. Angiotensin II induces ovulation and oocyte maturation in rabbit ovaries via the AT2 receptor subtype. Endocrinology. 1996;137(4):1204-1211.
29. Breault L, Lehoux JG, Gallo-Payet N. The angiotensin AT2 receptor is present in the human fetal adrenal gland throughout the second trimester of gestation. J Clin Endocrinol Metab. 1996;81(11):3914-3922.
30. Johnson MC, Vega M, Vantman D, Troncoso JL, Devoto L. Regulatory role of angiotensin II on progesterone production by cultured human granulosa cells. Expression of angiotensin II type-2 receptor. Mol Hum Reprod. 1997;3(8):663-668.
31. Gonçalves PB, Ferreira R, Gasperin B, Oliveira JF. Role of angiotensin in ovarian follicular development and ovulation in mammals: a review of recent advances. Reproduction. 2012;143(1):11-20.
32. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47(24):5995-6008.
33. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension. 2012;59(2):291-299.
34. Steckelings UM, Larhed M, Hallberg A, et al. Non-peptide AT2-receptor agonists. Curr Opin Pharmacol. 2011;11(2):187-192.
35. Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118(24):2523-2532.
36. Ohshima K, Mogi M, Jing F, et al. Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPAR7 activation. PLoS One. 2012;7(11):e48387.
37. Shum M, Pinard S, Guimond MO, et al. Angiotensin II type 2 receptor promotes adipocyte differentiation and restores adipocyte size in high-fat/high-fructose diet-induced insulin resistance in rats. Am J Physiol Endocrinol Metab. 2013;304(2):E197-E210.
38. Shi D, Dyck MK, Uwiera RR, Russell JC, Proctor SD, Vine DF. A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome. Endocrinology. 2009;150(9):4425-36.
39. Wu-Peng XS, Chua SC Jr, Okada N, Liu SM, Nicolson M, Leibel RL. Phenotype of the obese Koletsky (f) rat due to Tyr763Stop mutation in the extracellular domainofthe leptin receptor (Lepr): evidence for deficient plasma-to-CSF transport of leptin in both the Zucker and Koletsky obese rat. Diabetes. 1997;46(3):513-518.
40. Donato J Jr, Cravo RM, Frazão R, Elias CF. Hypothalamic sites of leptin action linking metabolism and reproduction. Neuroendocri-nology. 2011;93(1):9-18.
41. Zhang Y, Hu M, Ma H, et al. The impairment of reproduction in db/db mice is not mediated by intraovarian defective leptin signaling. Fertil Steril. 2012;97(5):1183-1191.
42. 2receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension. 2011;57(2):308-313.
43. Joseph JP, Mecca AP, Regenhardt RW, et al. The angiotensin type 2 receptor agonist compound 21 elicits cerebroprotection in endo-thelin-1 induced ischemic stroke. Neuropharmacology. 2014;81: 134-141.
44. Kasim-Karakas SE, Almario RU, Gregory L, Wong R, Todd H, Lasley BL. Metabolic and endocrine effects of a polyunsaturated fatty acid-rich diet in polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89(2):615-620.
45. Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epide-miologic studies. Am J Epidemiol. 2000;151(2):190-198.
46. Snitker S, Le KY, Hager E, Caballero B, Black MM. Association of physical activity and body composition with insulin sensitivity in a community sampleofadolescents. Arch Pediatr Adolesc Med. 2007; 161(7):677-683.
47. Ci X, Frisch F, Lavoie F, et al. The effect of insulin on the intracellular distribution of 14(R, S)-[18F]Fluoro-6-thia-heptadecanoic acid in rats. Mol Imaging Biol. 2006;8(4):237-244.
48. Brock BJ, Waterman MR. Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species. Biochemistry. 1999;38(5):1598-1606.
49. Russell JC, Amy RM. Early atherosclerotic lesions in a susceptible rat model. The LA/N-corpulent rat. Atherosclerosis. 1986;60(2): 119-129.
50. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev En-docrinol. 2011;7(4):219-231.
51. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia inwomen with polycystic ovary syndrome. Am J Med. 2001;111(8):607-613.
52. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84(1): 165-169.
53. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007;5(4):496-501.
54. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am. 2001;28(1):111-133, vii.
55. Carpentier AC, Labbe SM, Grenier-Larouche T, Noll C. Abnormal dietary fatty acid metabolic partitioning in insulin resistance and type 2 diabetes. Clin Lipidol. 2011;6(6):703-716.
56. Kang J, Sumners C, Posner P. Angiotensin II type 2 receptor-modulated changes in potassium currents in cultured neurons. Am J Physiol. 1993;265(3 pt 1):C607-C616.
57. Lenkei Z, Palkovits M, Corvol P, Llorens-Cortès C. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neu-roendocrinol. 1997;18(4):383-439.
58. Danyel LA, Schmerler P, Paulis L, Unger T, Steckelings UM. Impact of AT2-receptor stimulation on vascular biology, kidney function, and blood pressure. Integr Blood Press Control. 2013; 6:153-161.
59. Nelson-Degrave VL, Wickenheisser JK, Hendricks KL, et al. Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol. 2005;19(2):379-390.
60. Ménard SL, Croteau E, Sarrhini O, et al. Abnormal in vivo myo-cardial energy substrate uptake in diet-induced type 2 diabetic car-diomyopathyin rats. Am J Physiol Endocrinol Metab. 2010;298(5): E1049-E1057.
61. Mangat R, Su J, Scott PG, Russell JC, Vine DF, Proctor SD. Chy-lomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome. Biochem Soc Trans. 2007;35(pt 3):477-481.